Propofol: Therapeutic indications and side-effects

被引:395
作者
Marik, PE [1 ]
机构
[1] Univ Pittsburgh, Dept Critical Care, Med Ctr, Pittsburgh, PA 15261 USA
关键词
propofol; metabisulfite; status epilepticus; status asthmaticus; traumatic brain injury; delirium tremens; sepsis; propofol-infusion syndrome; pancreatitis; allergy;
D O I
10.2174/1381612043382846
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Propofol (2, 6-diisopropylphenol) is a potent intravenous hypnotic agent which is widely used for the induction and maintenance of anesthesia and for sedation in the intensive care unit. Propofol is an oil at room temperature and insoluble in aqueous solution. Present formulations consists of 1% or 2% (w/v) propofol, 10% soyabean oil, 2.25% glycerol. and 1.2% egg phosphatide. Disodium edetate (EDTA) or metabisulfite is added to retard bacterial and fungal growth. Propofol is a global central nervous system depressant. It directly activates GABA(A) receptors. In addition, propofol inhibits the NMDA receptor and modulates calcium influx through slow calcium ion channels. Propofol has a rapid onset of action with a dose-related hypnotic effect. Recovery is rapid even after prolonged use. Propofol decreases cerebral oxygen consumption, reduces intracranial pressure and has potent anti-convulsant properties. It is a potent antioxidant. has anti-inflammatory properties and is a bronchodilator. As a consequence of these properties propofol is being increasingly used in the management of traumatic head injury, status epilepticus, delirium tremens, status asthmaticus and in critically ill septic patients. Propofol has a remarkable safety profile. Dose dependent hypotension is the commonest complication; particularly in volume depleted patients. Hypertriglyceridemia and pancreatitis are uncommon complications. Allergic complications, which may include bronchospasm, have been reported with the formulation containing metabisulfite. In addition, this formulation has been demonstrated to result in the generation of oxygen free radicals. High dose propofol infusions have been associated with the "propofol syndrome"; this is a potentially fatal complication characterized by severe metabolic acidosis and circulatory collapse. This is a rare complication first reported in pediatric patients and believed to be due to decreased transmembrane electrical potential and alteration of electron transport across the inner mitochondrial membrane.
引用
收藏
页码:3639 / 3649
页数:11
相关论文
共 209 条
[1]
DOUBLE-BLIND-STUDY OF ALPRAZOLAM, DIAZEPAM, CLONIDINE, AND PLACEBO IN THE ALCOHOL-WITHDRAWAL SYNDROME - PRELIMINARY FINDINGS [J].
ADINOFF, B .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1994, 18 (04) :873-878
[2]
COMPARISON OF PROPOFOL AND MIDAZOLAM FOR SEDATION IN CRITICALLY ILL PATIENTS [J].
AITKENHEAD, AR ;
WILLATTS, SM ;
PARK, GR ;
COLLINS, CH ;
LEDINGHAM, IM ;
PEPPERMAN, ML ;
COATES, PD ;
BODENHAM, AR ;
SMITH, MB ;
WALLACE, PGM .
LANCET, 1989, 2 (8665) :704-709
[3]
A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus [J].
Alldredge, BK ;
Gelb, AM ;
Isaacs, SM ;
Corry, MD ;
Allen, F ;
Ulrich, S ;
Gottwald, MD ;
O'Neil, N ;
Neuhaus, JM ;
Segal, MR ;
Lowenstein, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (09) :631-637
[4]
PROPOFOL REDUCES NEURONAL TRANSMISSION DAMAGE AND ATTENUATES THE CHANGES IN CALCIUM, POTASSIUM, AND SODIUM DURING HYPERTHERMIC ANOXIA IN THE RAT HIPPOCAMPAL SLICE [J].
AMORIM, P ;
CHAMBERS, G ;
COTTRELL, J ;
KASS, IS .
ANESTHESIOLOGY, 1995, 83 (06) :1254-1265
[5]
WHY WAS THE URINE GREEN [J].
ANANTHANARAYAN, C ;
FISHER, JA .
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 1995, 42 (01) :87-88
[6]
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].
Angus, DC ;
Linde-Zwirble, WT ;
Lidicker, J ;
Clermont, G ;
Carcillo, J ;
Pinsky, MR .
CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310
[7]
Compartmentalised inducible nitric-oxide synthase activity in septic shock [J].
Annane, D ;
Sanquer, S ;
Sébille, V ;
Faye, A ;
Djuranovic, D ;
Raphaël, JC ;
Gajdos, P ;
Bellissant, E .
LANCET, 2000, 355 (9210) :1143-1148
[8]
[Anonymous], J CRIT ILLN
[9]
Infectious risks associated with the use of propofol [J].
Bach, A ;
Motsch, J .
ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1996, 40 (10) :1189-1196
[10]
Metabolic acidosis associated with a new formulation of propofol [J].
Badr, AE ;
Mychaskiw, G ;
Eichhorn, JH .
ANESTHESIOLOGY, 2001, 94 (03) :536-538